




(86) Date de dépôt PCT/PCT Filing Date: 2008/09/19
(87) Date publication PCT/PCT Publication Date: 2009/03/26
(85) Entrée phase nationale/National Entry: 2010/03/19
(86) N° demande PCT/PCT Application No.: CA 2008/001658
(87) N° publication PCT/PCT Publication No.: 2009/036571
(30) Priorité/Priority: 2007/09/21 (US60/974,228)

(51) Cl.Int./Int.Cl. *A61L 31/16* (2006.01),
A61F 11/00 (2006.01), *A61K 33/00* (2006.01),
A61L 31/04 (2006.01)
(71) Demandeur/Applicant:
ENOX BIOPHARMA, INC., CA
(72) Inventeurs/Inventors:
AV-GAY, YOSSEF, CA;
GREENBERG, DAVID, CA
(74) Agent: GOWLING LAFLEUR HENDERSON LLP

(54) Titre : TUBES ANTIMICROBIENS LIBERANT UN GAZ POUR DRAINER L'OREILLE
(54) Title: ANTIMICROBIAL GAS-RELEASING EAR DRAINAGE TUBES

Fig 1(a)



(57) **Abrégé/Abstract:**

A nitric oxide gas-releasing conduit configured for surgical implantation through a patient's tympanic membrane. The nitric oxide gas-releasing conduit comprises a gas-permeable cured resin material configured for releasably sequestering therein gas. The gas-



(57) **Abrégé(suite)/Abstract(continued):**

permeable cured resin material is charged with nitric oxide gas. The nitric oxide gas-releasing conduit may be optionally coated with an antimicrobial gas-releasing composition. The gas-releasing coating composition may be configured to release nitric oxide.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 March 2009 (26.03.2009)

PCT

(10) International Publication Number
WO 2009/036571 A1

(51) International Patent Classification:

A61L 31/16 (2006.01) *A61K 33/00* (2006.01)
A61F 11/00 (2006.01) *A61L 31/04* (2006.01)

(74) Agent: **POLOENKO, Daniel**; c/o Fasken Martineau
DuMoulin LLP, 2900 - 550 Burrard Street, Vancouver,
British Columbia V6C 0A3 (CA).

(21) International Application Number:

PCT/CA2008/001658

(22) International Filing Date:

19 September 2008 (19.09.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/974,228 21 September 2007 (21.09.2007) US

(71) Applicant (for all designated States except US): **ENOX
BIOPHARMA, INC.** [CA/CA]; 3849 West 13th Avenue,
Vancouver, British Columbia V6R 2S9 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **AV-GAY, Yossef**
[CA/CA]; c/o 3849 West 13th Avenue, Vancouver, British
Columbia V6R 2S9 (CA). **GREENBERG, David** [IL/IL];
c/o 3849 West 13th Avenue, Vancouver, British Columbia
V6R 2S9 (CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID,
IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK,
LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW,
MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL,
NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG,
CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(54) Title: ANTIMICROBIAL GAS-RELEASING EAR DRAINAGE TUBES

Fig 1(a)



(57) Abstract: A nitric oxide gas-releasing conduit configured for surgical implantation through a patient's tympanic membrane. The nitric oxide gas-releasing conduit comprises a gas-permeable cured resin material configured for releasably sequestering therein gas. The gas-permeable cured resin material is charged with nitric oxide gas. The nitric oxide gas-releasing conduit may be optionally coated with an antimicrobial gas-releasing composition. The gas-releasing coating composition may be configured to release nitric oxide.

WO 2009/036571 A1

ANTIMICROBIAL GAS-RELEASING EAR DRAINAGE TUBES

TECHNICAL FIELD

This invention relates to ear drainage tubes. More particularly, this invention relates to gas-releasing antimicrobial ear drainage tubes.

BACKGROUND ART

5 Installation of tympanostomy tubes for the treatment of otitis media with effusion or in patients with recurrent events of acute otitis media, is a commonly performed surgical procedure in North America and elsewhere. In this procedure an incision is made in the tympanic membrane, fluid from within the middle ear is aspirated and a tympanostomy tube is inserted. The tubes can
10 have various configurations and materials, and are effective in correcting the hearing loss due to the effusion as long as the tubes are in place in the ear. The materials which can be used to make tympanostomy tubes include thermoplastics such as modified elastomers and olefins, thermosets such as silicone and polytetrafluoroethylene; and metals such as stainless steel and
15 titanium. Children with persistent middle ear effusions who do not respond to antibiotics undergo a procedure in which a myringotomy is performed in the tympanic membrane under local anesthesia. However the implantation of the tympanostomy tubes also be done under general anesthesia.

 Purulent otorrhea frequently develops after tube insertion. In one study
20 by H. G. Birck and J. J. Mravek "Myringotomy for Middle Ear Effusions," Ann. of Otol. Rhino. Laryngo., volume 85, pages 263-267 (1979), the investigators observed that 15% of children having tympanostomy tubes inserted in their ears following myringotomy developed postoperative otorrhea. In a more recent study by George A. Gates et al, "Post Tympanostomy
25 Otorrhea," Laryngoscope, volume 96, pages 630-634, (June 1986), the investigators observed that the incidence of tympanostomy tube induced otorrhea following myringotomy was 18%. In a clinical study performed by Balkany et al, "A Prospective Study of Infection Following Tympanostomy and Tube Insertion," American Journal of Otology, volume 4, pages 288-291

(1983), the investigators observed an incidence of postoperative otorrhea of 19% in children receiving tympanostomy tubes with no antibiotic drops postoperatively applied. In the Balkany et al study, the investigators found that the incidence of postoperative otorrhea was reduced to 6% when antibiotic drops were put into the patient's ear after myringotomy. In another study on the use of antibiotics after myringotomy, R. S. Baker and R. A. Chole, "A Randomized Clinical Trial of Topical Gentamicin After Tympanostomy Tube Placement," Arch. Otolaryngology Head and Neck Surgery, volume 114, pages, 755-757 (July 1988), the investigators found that the incidence of infections in the experimental group using Gentamicin, an ophthalmic solution used as otic drops, had an incidence of infection significantly reduced by antibiotic drops.

In both the Balkany et al and Baker et al studies using antibiotic drops after tympanostomy, the investigators used potentially ototoxic antibiotics, namely Cortisporin and Gentamicin. Based on their frequency of use, and the lack of adverse effects noted in these studies, antibiotic drops are now used routinely to prevent postoperative otorrhea. However, thorough studies demonstrating the absence of adverse toxicological reaction in the use of antibiotic drugs for the treatment of postoperative otorrhea have not been published.

In addition to the relatively high incidence of otorrhea after myringotomy, investigators have observed children with implanted tympanostomy tubes sometimes experience bouts of otorrhea. Occasionally, the otorrhea became persistent causing some investigators to believe that the tympanostomy tubes become colonized with pathogenic bacteria.

The relatively high incidence of otorrhea after myringotomy and tympanostomy tube insertion exposes patients with persistent middle ear effusions to significant morbidity and additional treatment time and cost.

It would be desirable to utilize tympanostomy tubes whereby the incidence of otorrhea and other microbial induced infection after myringotomy and tympanostomy tube insertion could be substantially reduced without the

use of antibiotics and the potential ototoxic reaction associated with the use of such drugs.

One approach for reducing bacterial infection encountered with the use of medical devices inserted into body cavities has been to apply an antimicrobial coating to the surface of the medical device. For example, U.S. Pat. No. 4,592,920 to Murtfeldt; U.S. Pat. No. 4,603,152 to Laurin et al and U.S. Pat. No. 4,677,143 to Laurin et al each teach applying a coating containing an antimicrobial agent such as silver oxide to the outer surfaces of medical devices such as catheters, enteral feeding tubes, endotracheal tubes and other hollow tubular devices.

U.S. Patent No. 4,592,920 to Murtfeldt is primarily concerned with providing a surface coating of an antimicrobial metal compound on a medical device such as a catheter, but also discloses that the metal compound can be "imbedded" within the entire catheter. However, the Murtfeldt patent finds the imbedded construction to be less desirable since the antimicrobial metal compound imbedded within the side wall of the catheter has less likelihood of encountering migrating microbes and by inference is less effective than a surface coating.

U.S Patent No. 6,361,526 provides a tube formed from a thermoset resin containing therein between 0.5 to 15% by weight of a selected antimicrobial metal oxide compounds exemplified by silver oxide, that are capable of migrating to the sidewall surfaces of the tube. Such metal oxide-laden antimicrobial resin-based tubes are generally produced by controllably intermixing a selected metal oxide into a thermoset resin paste that is subsequently milled, then formed into a hollow tube by conventional tube-forming processes.

DISCLOSURE OF THE INVENTION

The exemplary embodiments of the present invention, are directed to antimicrobial gas-permeable gas-releasing conduits suitable for surgical implantation into and through patients' tympanic membranes. Suitable gas-

permeable conduits are exemplified by tympanostomy tubes, myringotomy tubes and the like.

According to one aspect, the cured gas-permeable gas-releasing resin material comprises curable silicones.

5 According to another aspect, the antimicrobial gas-permeable gas-releasing molecules are exemplified by nitric oxide (NO) molecules.

According to another aspect the NO gas-permeable gas-releasing implantable conduits are coated with NO-releasing compositions exemplified by those having N_2O_2^- functional groups, NO-releasing intramolecular salts,
10 and S-nitrosothiols among others.

According to further aspect, the antimicrobial gas-permeable gas-releasing conduits are exemplified by tympanostomy tubes.

According to a further aspect, the antimicrobial gas-permeable gas-releasing conduits are exemplified by myringotomy tubes.

15 According to another exemplary embodiment of the present invention, the antimicrobial gas-permeable gas-releasing conduits are produced with a process whereby fully configured and cured gas-permeable resin-based tubes are controllably saturated with a selected antimicrobial gas exemplified by NO, whereby the resin-based tubes releasably sequester NO gas molecules. The
20 antimicrobial gas-saturated conduits are individually packaged in gas-impermeable containers.

According to one aspect, the resin-based conduits sequestering therein NO gas molecules, are coated with NO-releasing compositions exemplified by those having N_2O_2^- functional groups, NO-releasing intramolecular salts, and S-
25 nitrosothiols among others.

According to a further embodiment, the antimicrobial gas-releasing conduits are produced by intermixing a suitable selected chelating agent saturated with antimicrobial gas molecules, with a curable polymeric resin material. The intermixed material is formed and configured into a plurality of
30 antimicrobial gas-releasing conduits, then cured. After curing, the antimicrobial

gas-releasing conduits are individually packaged and sealed into gas-impermeable containers.

BRIEF DESCRIPTION OF THE DRAWINGS

5 The present invention will be described in conjunction with reference to the following drawings, in which:

Fig. 1(a) is a chart showing the effects of gNO released from gNO-charged vent tubes on the proliferation of *Streptococcus pyogenes*. Fig 1(b) is a chart showin the effects of released gNO on survival of *S. pyogenes*;

10 Fig. 2(a) is a chart showing the effects of gNO released from gNO-charged vent tubes on the proliferation of *Streptococcus pneumonia*. Fig 2(b) is a chart showin the effects of released gNO on survival of *S. pneumonia*;

Fig. 3(a) is a chart showing the effects of gNO released from gNO-charged vent tubes on the proliferation of *Moraxella catarrhalis*. Fig 3(b) is a chart showin the effects of released gNO on survival of *M. catarrhalis*;

15 Fig. 4(a) is a chart showing the effects of gNO released from gNO-charged vent tubes on the proliferation of *Haemophilus influenzae*. Fig 4(b) is a chart showin the effects of released gNO on survival of *H. influenzae*;

Fig. 5(a) is a chart showing the effects of gNO released from gNO-charged vent tubes on the proliferation of methicillin-resistant *Staphylococcus aureus*. Fig 5(b) is a chart showin the effects of released gNO on survival of *S. aureus*; and

20

Fig. 6 is a chart showing the effects of gNO released from gNO-charged silicon vent tubes and gNO-charged polytetrafluoroethylene vent tubes on the proliferation of *Staphylococcus aureus*.

25 DETAILED DESCRIPTION OF THE INVENTION

The exemplary embodiments of the present invention are directed to antimicrobial conduit structures configured for long-term installation through

the tympanic membranes into the inner ear cavities for the purpose of draining fluids therefrom. Such conduit structures are exemplified by tympanostomy tubes, myringotomy ventilation tubes and the like, and will be generally referred to from hereon in as "tympanostomy tubes". The antimicrobial
5 tympanostomy tubes according to the present invention generally comprise materials that are controllably permeatable with gases selected for their antimicrobial properties.

The antimicrobial tympanostomy tubes of the present invention are characterized by their biological compatibility with otologic tissue associated
10 with the tympanic membrane and middle ear tissues, and generally comprise polymeric materials exemplified by resins which after forming and curing, are microporous and have the requisite high gas permeability properties needed to prepare the antimicrobial tympanostomy tubes of the present invention. These resins are suitably characterized by an ability for infiltratably sequestering
15 selected permeating antimicrobial gases, and then controllably releasing the antimicrobial gases over extended periods of time. Suitable resins are exemplified by curable silicones, polyvinyl acetates, thermoplastic elastomers, acrylonitrile-butadiene-styrene copolymer rubber, polyurethanes and the like. Curable silicone resins are preferred for the manufacture of the antimicrobial
20 tympanostomy tubes of the present invention due to their molecular structure which provides good flexibility both microscopically and macroscopically, and high gas permeability rates. Table 1 illustrates the gas permeability of silicone resins in comparison with other types of materials suitable for such tubular manufacture.

25 The geometries of the antimicrobial tympanostomy tubes are generally cylindrical and may simply comprise elongate hollow conduits having the same diameter extending from end to end, or alternatively may comprise elaborate configurations that may additionally include abrupt diameter changes and odd shaped flanges.

Table 1: Gas permeation through selected materials (cc/0.001in/100.0 in²/24 h at 22.8° C, 0% relative humidity, ASTM D-1434)*.

Tubular material	Permeating gas	
	O ₂	CO ₂
Silicone	50,000	300,000
Urethanes	200	3,000
Epoxies	5-10	8
Fluorocarbons	7-15	15-30
Nylon	2.6	4.7
Polybutylene	385	825
Polycarbonate	258	775
Cellulose acetate	23	105

* adapted from; (1) Packaging Encyclopedia 1988 Vol. 33 No. 5, pp. 54-55, and Machine Design, May 25, 1967, p. 192.

5 Gaseous nitric oxide (gNO) is an intermediary compound produced during the normal functioning of numerous biochemical pathways in many biological systems including humans. gNO is known to those skilled in these arts as a key biological messenger signaling compound that plays key roles in many biological processes. Recent evidence (e.g., Ghaffari et al., 2005 Nitric
10 Oxide 14: 21-29) suggests that gNO plays an important role in mammalian host defense against infection and regulates wound healing and angiogenesis. In particular, topical applications of exogenous gNO at 200 ppm for extended periods of time inhibited and prevented the growth of a wide range of microbial pathogens *Staphylococcus aureus*, *Escherichia coli*, Group B *Streptococcus*,
15 *Pseudomonas aeruginosa*, and *Candida albicans*, without any cytotoxic effects on cultured human dermal fibroblasts. Furthermore, McMullin et al. (2005, Respir. Care 5:1451-1456) demonstrated that exogenous gNO at a concentration of 200 ppm could clear nosocomial pneumonia caused by microbial pathogens such as *S. aureus* and *P. aeruginosa*, in about 6 hours.
20 Accordingly, gNO is a particularly suitable antimicrobial gas for saturatingly permeating tympanostomy tubes comprising gas-permeable polymeric materials.

The antimicrobial typanostomy tubes of the present invention are produced by first casting a desired tubular configuration with a selected suitable
25 resin using conventional methods known to those skilled in these arts. It is

suitable to process the tubes into their final configuration and finish after which, the tubes are placed into a sealable chamber. The chamber is then saturated with a selected antimicrobial gas, exemplified by gNO, for a selected period of time suitable for infiltratingly saturating the tympanostomy tubes whereby the gas is sequestered into and within the resin structure comprising the tubes thereby by providing antimicrobial properties to the tympanostomy tubes. Excess gNO is then evacuated from the chamber after which, the gNO-loaded tympanostomy tubes are removed and individually packaged into gas-impermeable containers. It is within the scope of the present invention to infiltrate the chamber with a semi-porous sealing gaseous material configured to at least partially cross-link with the outer surfaces antimicrobial tympanostomy tubes thereby enabling a further extension of time duration for release of the sequestered gas about the antimicrobial tympanostomy tubes. The chamber may be controllably infiltrated with the semi-porous sealing gaseous material concurrently with evacuation of the antimicrobial gas from the chamber or alternatively, the antimicrobial gas may be completely evacuated from the chamber after which, the semi-porous sealing gaseous material may be infiltrated into the chamber. Excess semi-porous sealing gaseous material is then evacuated from the chamber after which, the gNO-loaded tympanostomy tubes are removed and individually packaged into gas-impermeable containers.

It is also within the scope of the present invention to incorporate gNO-sequestering chelating agents into a suitable selected resin material prior to forming tympanostomy tubes. Suitable gNO-sequestering chelating agents are exemplified by sodium nitrite, nitrosothiols, dipyridoxyl chelating agents, L-arginine, organic nitrates, organic nitrites, thionitrates, thionitrites, N-oxo-N-nitrosamines, N-nitrosamines, sydnonimines, 2-hydroxyimino-5-nitro-alkenamides, diazenium diolates, oxatriazolium compounds, oximes, syndomines, molsidomine and derivatives thereof, pirsidomine, furoxanes, nitrosonium salts, and the like, and combinations thereof. A suitable amount of a selected gNO-sequestering chelating agent is placed into a sealable chamber which is then saturated with gNO. A suitable amount of the gNO-loaded chelating agent is then thoroughly intermixed and commingled with a selected resin material after which, the resin material is processed into tympanostomy

tubes using methods known to those skilled in these arts. The tympanostomy tubes comprising interspersed therethrough gNO-loaded chelating agent, are then sealably packaged into gas-impermeable containers.

It is also within the scope of the present invention to provide an
5 antimicrobial gas-releasing coating onto the outer surfaces, and optionally on to the inner surfaces, of NO gas-permeated tympanostomy tubes of the present invention. For example, NO gas-releasing coatings can be provided by applying to the NO gas-permeated tympanostomy tubes, a composition comprising a N_2O_2^- functional group that will bind to the cured resin material
10 comprising the tympanostomy tubes. Suitable exemplary compounds comprising N_2O_2^- functional groups are disclosed in US Patent Number 5,525,357. Other suitable exemplary coating compositions for providing NO gas-releasing coatings onto NO gas-permeated tympanostomy tubes include among others, NO-releasing intramolecular salts known as zwitterions having
15 the general formula $2\text{RN}[\text{N}(\text{O})\text{NO}^-(\text{CH}_2)_n\text{NH}_2^+\text{R}']$, and S-nitrosothiols.

An antimicrobial gas-permeated tympanostomy tube of the present invention can be surgically implanted using well-known procedures, through a patient's tympanic membrane such that one end of the tympanostomy tube extends into the patient's middle ear cavity while the other end of the tube
20 extends through the tympanic membrane into the outer ear cavity. The antimicrobial gas sequestered within the resin material comprising the implanted tympanostomy tube will slowly diffuse from and about the tube thereby alleviating and/or preventing post-operative microbial infections normally associated with these types of tubes and without adverse toxicology
25 reactions exemplified by irritation and inflammation, of otologic tissues. Contact with moisture will expedite the release of gNO sequestered within and coated onto the antimicrobial tympanostomy tubes of the present invention. Furthermore, provision of NO gas-releasing coatings on the outer surfaces of the tubes, and optionally on their inner surfaces, will inhibit and prevent the
30 formation of biofilms thereon.

EXAMPLES

EXAMPLE 1

A plurality of vent tubes comprising a polytetrafluoroethylene (PTFE) substrate (1.25 mm Sheehy collar buttons, catalog number 23-40300; Inovotec International Inc., Jacksonville, FL, USA) were placed into gas-ventable Petri dishes. A suitable catheter was used to connect the Petri dishes to a manifold connected to a cylinder containing gNO manufactured by Airgas (Chicago IL, USA). The manifold was provided with a gas flow controller adjusted to deliver 22,000 ppm of gNO to each Petri dish at a flow rate of 30 cc min⁻¹ for a period of 22 h. After the gNO-charging process was completed, the gNO-charged PTFE vent tubes were stored in gas-impermeable containers. All handling of the vent tubes after the gNO-charging process was completed, was done using aseptic techniques.

Stock cultures of *Streptococcus pyogenes* (ATCC# 51878), *Streptococcus pneumonia* (ATCC# 10015), *Moraxella catarrhalis* (ATCC# 25240), and *Haemophilus influenzae* (ATCC# 35540) were maintained on nutrient agar. Broth cultures of each microorganism were prepared by inoculating a test tube containing 10 mL of Brain Heart Infusion broth with a colony picked from a stock culture plate. The inoculated test tubes were cultured for 12 h to 18 h at 37° C in an incubator provided with an atmosphere containing about 5% CO₂. The cultures were then diluted with fresh Brain Heart Infusion broth to an OD₆₀₀ reading of 0.5. Each broth culture thus prepared contained 10⁷ to 10⁸ colony-forming units (CFU) mL⁻¹. All handling of the microbial cultures was done using aseptic techniques.

All wells in a 24-well plate received 1 mL of broth culture of a selected microorganism prepared as described above. Each of 12 wells received 1 gNO-charged PTFE vent tube prepared as described above. Each of the remaining 12 wells received 1 sterile PTFE vent tube as supplied by the manufacturer. The tubes were incubated in the broth cultures contained in the 24-well plates for about 1 min after which, each tube was removed from its broth culture and transferred to a quadrant in a quadrant Petri dish. The quadrant Petri dishes

were maintained for 7 h at 37° C in an incubator provided with an atmosphere containing about 5% CO₂. Individual tubes were removed from the quadrant Petri dishes after 3 h and 7 h of incubation, and were each placed into a microtubes containing 30 µL of sterile phosphate-buffered saline (PBS) and
5 vortexed. The PBS was then pipetted onto a nutrient agar plate and spread across the agar surface. The inoculated plates were then incubated for 24 h at 37° C in an incubator provided with an atmosphere containing about 5% CO₂ after which, the plates were removed and the numbers of CFU units appearing thereon were quantified. The results are shown in Figs. 1-4. The data show that
10 exposure of *S. pyogenes* (Figs. 1(a) and 1(b)), *S. pneumonia* (Figs. 2(a) and 2(b)), *M. catarrhalis* (Figs. 3(a) and 3(b)), and *H. influenzae* (Figs. 4(a) and 4(b)) to gNO-charged vent tubes reduced the proliferation of each of the microbial species tested.

EXAMPLE 2

15 A plurality of vent tubes comprising a PTFE substrate (Armstrong Beveled vent tube Grommet-type 1.14 mm I.D Fluorplastic, from Gyrus ACMI, catalog number 140242; Inovotec International Inc., Jacksonville, FL, USA) were placed into gas-ventable Petri dishes. A suitable catheter was used to connect the Petri dishes to a manifold connected to a cylinder containing gNO
20 manufactured by Airgas (Chicago IL, USA). The manifold was provided with a gas flow controller adjusted to deliver 22,000 ppm of gNO to each Petri dish at a flow rate of 30 cc min⁻¹ for a period of 22 h. After the gNO-charging process was completed, the gNO-charged PTFE vent tubes were stored in gas-impermeable containers. All handling of the vent tubes after the gNO-charging
25 process was completed, was done using aseptic techniques.

A stock culture of methicillin-resistant *Staphylococcus aureus* (MRSA; ATCC# 700698), was maintained on nutrient agar. MSRA is a *S. aureus* strain that is known to be resistant to a number of broad-spectrum antibiotics commonly used to treat it. MRSA broth cultures were prepared by inoculating
30 a plurality of test tubes containing 10 mL of Brain Heart Infusion broth with a colony picked from a stock culture plate. The inoculated test tubes were cultured for 12 h to 18 h at 37° C in an incubator provided with an atmosphere

containing about 5% CO₂. The cultures were then diluted with fresh Brain Heart Infusion broth to an OD₆₀₀ reading of 0.5. Each broth culture thus prepared contained about 10⁵ CFU mL⁻¹. All handling of the microbial cultures was done using aseptic techniques.

5 All wells in a 24-well plate received 1 mL of a MSRA broth culture prepared as described above. Each of 12 wells received 1 gNO-charged PTFE vent tube prepared as described above. Each of the remaining 12 wells received 1 sterile PTFE vent tube as supplied by the manufacturer. The tubes were incubated in the broth cultures contained in the 24-well plates for about 1 min
10 after which, each tube was removed from its broth culture and transferred to a quadrant in a quadrant Petri dish. The quadrant Petri dishes were maintained for 7 h at 37° C in an incubator provided with an atmosphere containing about 5% CO₂. Individual tubes were removed from the quadrant Petri dishes after 3 h and 7 h of incubation, and were each placed into a microtubes containing 30 µL
15 of sterile phosphate-buffered saline (PBS) and vortexed. The PBS was then pipetted onto a nutrient agar plate and spread across the agar surface. The inoculated plates were then incubated for 24 h at 37° C in an incubator provided with an atmosphere containing about 5% CO₂ after which, the plates were removed and the numbers of CFU units appearing thereon were quantified. The
20 results are shown in Fig. . The data show that exposure of methicillin-resistant *Staphylococcus aureus* (Figs. 5(a) and 5(b)) to gNO-charged vent tubes reduced the proliferation of this microbial species.

EXAMPLE 3

A first plurality of vent tubes comprising a silicon substrate (T-Tube, 25 Silicon Myringotomy Tube, 23-50600; Invotec International Inc., Jacksonville, FL, US) and a second plurality of vent tubes a PTFE substrate (Sheehy Collar Button, Fluoroplastic Myringotomy Tube, 23-40300; Inovotec International Inc., Jacksonville, FL, USA) were placed into gas-ventable Petri dishes. A suitable catheter was used to connect the Petri dishes to a manifold connected to a
30 cylinder containing gNO manufactured by Airgas (Chicago IL, USA). The manifold was provided with a gas flow controller adjusted to deliver 22,000 ppm of gNO to each Petri dish at a flow rate of 30 cc min⁻¹ for a period of 22 h.

After the gNO-charging process was completed, the gNO-charged silicon vent tubes and PTFE vent tubes were stored in gas-impermeable containers. All handling of the vent tubes after the gNO-charging process was completed, was done using aseptic techniques.

5 A stock culture of a *Staphylococcus aureus* (ATCC# 25923), was maintained on nutrient agar. *S. aureus* broth cultures were prepared by inoculating a plurality of test tubes containing 10 mL of Brain Heart Infusion broth with a colony picked from a stock culture plate. The inoculated test tubes were cultured for 12 h to 18 h at 37° C in an incubator provided with an
10 atmosphere containing about 5% CO₂. The cultures were then diluted with fresh Brain Heart Infusion broth to an OD₆₀₀ reading of 0.5. Each broth culture thus prepared contained about 10⁵ CFU mL⁻¹. All handling of the microbial cultures was done using aseptic techniques.

 All wells in a 24-well plate received 1 mL of a *S. aureus* broth culture
15 prepared as described above. Each of 12 wells received 1 gNO-charged PTFE vent tube prepared as described above. Each of the remaining 12 wells received 1 sterile PTFE vent tube as supplied by the manufacturer. The tubes were incubated in the broth cultures contained in the 24-well plates for about 1 min after which, each tube was removed from its broth culture and transferred to a
20 quadrant in a quadrant Petri dish. The quadrant Petri dishes were maintained for 7 h at 37° C in an incubator provided with an atmosphere containing about 5% CO₂. Individual tubes were removed from the quadrant Petri dishes after 3 h and 7 h of incubation, and were each placed into a microtubes containing 30 µL of sterile phosphate-buffered saline (PBS) and vortexed. The PBS was then
25 pipetted onto a nutrient agar plate and spread across the agar surface. The inoculated plates were then incubated for 24 h at 37° C in an incubator provided with an atmosphere containing about 5% CO₂ after which, the plates were removed and the numbers of CFU units appearing thereon were quantified. The results are shown in Fig. . The data show that exposure of *S. aureus* ATCC#
30 25923 to gNO-charged vent tubes reduced the proliferation of this microbial species on silicon-based vent tubes and on PTFE vent tubes (Fig. 6).

While this invention has been described with respect to the exemplary embodiments, it is to be understood that various alterations and modifications can be made to the configurations and shapes of the antimicrobial tympanostomy tubes, and to methods for saturatingly infiltrating the tubes with
5 a selected antimicrobial gas within the scope of this invention, which are limited only by the scope of the appended claims.

What is claimed is:

1. An antimicrobial gas-releasing conduit configured for surgical implantation through a patient's tympanic membrane, the antimicrobial conduit comprising:
 - an elongate hollow tube comprising a gas-permeable cured resin material, said gas-permeable cured resin material configured for releasably sequestering therein permeating gases; and
 - a permeating antimicrobial gas releasably sequestered therein said gas-permeable resin material.
2. An antimicrobial conduit according to claim 1, wherein said gas-permeable cured resin material comprises a hydrophobic resin material.
3. An antimicrobial conduit according to claim 1, wherein said gas-permeable cured resin material is selected from the group consisting of curable silicones, polyvinyl acetates, thermoplastic elastomers, acrylonitrile-butadiene-styrene copolymer rubber, polyurethanes and selected combinations thereof.
4. An antimicrobial conduit according to claim 1, wherein said gas-permeable cured resin material is coated with an antimicrobial gas-releasing composition.
5. An antimicrobial conduit according to claim 1, wherein said permeating antimicrobial gas is nitric oxide.
6. An antimicrobial conduit according to claim 4, wherein said antimicrobial gas-releasing composition is configured to release nitric oxide.
7. An antimicrobial conduit according to claim 4, wherein said antimicrobial gas-releasing composition is selected from the group consisting of nitric oxide

gas-releasing intramolecular salts, S-nitrosothiols, compounds provided with N_2O_2^- functional groups, and combinations thereof.

8. An antimicrobial conduit according to claim 1, wherein said elongate hollow tube is a tympanostomy tube.

9. An antimicrobial conduit according to claim 1, wherein said elongate hollow tube is a myringotomy tube.

10. A process for producing an antimicrobial gas-releasing conduit suitable for surgical implantation through a patient's tympanic membrane, the process comprising:

placing into a sealable chamber, a plurality of selected conduits comprising a gas-permeable cured resin material, said gas-permeable cured resin material configured for releasably sequestering therein permeating antimicrobial gases;

sealing and then controllably saturating said chamber with a selected antimicrobial gas whereby the antimicrobial gas permeates into and is releasably sequestered therein the gas-permeable cured resin material;

controllably evacuating unsequestered antimicrobial gas from said sealed chamber and then unsealing the chamber; and

individually sealing each antimicrobial gas-saturated conduit within a gas-impermeable packaging.

11. A process according to claim 10, wherein said gas-impermeable cured resin comprises a hydrophobic resin material.

12. A process according to claim 10, wherein said gas-impermeable cured resin is selected from the group consisting of curable silicones, polyvinyl acetates, thermoplastic elastomers, acrylonitrile-butadiene-styrene copolymer rubber, polyurethanes and selected combinations thereof.

13. A process according to claim 10, wherein the antimicrobial gas is nitric oxide.
14. The process according to claim 10, wherein said elongate hollow tube is a tympanostomy tube.
15. The process according to claim 10, wherein said elongate hollow tube is a myringotomy tube.
16. The process according to claim 10, wherein said gas-permeable cured resin material sequestering therein a permeating antimicrobial gas, is coated with an antimicrobial gas-releasing composition prior to sealing said antimicrobial gas-saturated conduit within a gas-impermeable packaging.
17. The process according to claim 16, wherein said antimicrobial gas-releasing composition is configured to release nitric oxide gas.
18. The process according to claim 16, wherein said antimicrobial gas-releasing composition is selected from the group consisting of nitric oxide gas-releasing intramolecular salts, S-nitrosothiols, compounds provided with N_2O_2^- functional groups, and combinations thereof.
19. A process for producing a nitric oxide gas-releasing conduit suitable for surgical implantation through a patient's tympanic membrane, the process comprising:
 - commingling and intermixing a nitric-acid-saturated nitric-acid-chelating compound with a polymeric resin material capable of forming a gas-permeable cured resin;
 - producing and curing a plurality of nitric oxide gas-releasing conduits from said polymeric resin material intermixed with said nitric-acid-saturated nitric-acid-chelating compound; and

individually packaging and sealing said plurality of nitric oxide gas-releasing conduits into gas-impermeable containers.

20. A process according to claim 19, wherein the nitric-acid chelating compound is selected from the group comprising sodium nitrite, nitrosothiols, dipyridoxyl chelating agents, L- arginine, organic nitrates, organic nitrites, thionitrates, thionitrites, N-oxo-N-nitrosamines, N-nitrosamines, sydnonimines, 2-hydroxyimino-5-nitro-alkenamides, diazenium diolates, oxatriazolium compounds, oximes, syndomines, molsidomine and derivatives thereof, pirsidomine, furoxanes, nitrosonium salts, and combinations thereof.

21. A process according to claim 19, wherein the polymeric resin material is selected from the group consisting of curable silicones, polyvinyl acetates, thermoplastic elastomers, acrylonitrile-butadiene-styrene copolymer rubber, polyurethanes and combinations thereof.

22. The process according to claim 19, wherein said gas-permeable cured resin material sequestering therein nitric oxide gas, is coated with an antimicrobial gas-releasing composition prior to sealing said nitric oxide gas-releasing conduit within a gas-impermeable packaging.

23. The process according to claim 19, wherein said antimicrobial gas-releasing composition is configured to release nitric oxide gas.

24. The process according to claim 19, wherein said antimicrobial gas-releasing composition is selected from the group consisting of nitric oxide gas-releasing intramolecular salts, S-nitrosothiols, compounds provided with N_2O_2^- functional groups, and combinations thereof.

25. The process according to claim 19, wherein said elongate hollow tube is a tympanostomy tube.

26. The process according to claim 19, wherein said elongate hollow tube is a myringotomy tube.

Fig 1(a)




Fig 1(b)




Fig 2(a)




Fig 2(b)




Fig 3(a)




Fig 3(b)




Fig. 4(a)




Fig. 4(b)




Fig. 5(a)




Fig. 5(b)




Fig. 6




Fig 1(a)

